Johnson & Johnson

▲ Bull Case

• ◆Oncology compounding inflection underestimated: Darzalex entering front-line MM triplet/quadruplet combinations with peak sales to $10-11B+; Carvykti manufacturing scale resolving supply constraints to reach $3-4B by FY2028; Rybrevant+Lazcluze new NSCLC category with minimal consensus modeling—entire franchise worth more than current market cap on normalized multiples.
• ◆Pipeline option value nearly free: Milvexian (Factor XIa anticoagulant Phase 3) targets $20B+ anticoagulant market with superior safety profile; 20% probability × $5B peak sales × 10x multiple ≈ $20B total value (~$8/share option value). Icotrokinra (oral IL-23 first-in-class) has potential to disrupt $30B biologic IL-23 market. Neither asset in consensus models.
• ◆Talc resolution re-rates multiple: Negotiated global settlement in $9-12B range removes single largest discount factor, allowing P/E normalization to 22-24x. Even without settlement, faster court resolution pathway expands multiple toward peers.

▼ Bear Case

• ◆Talc litigation escalates beyond manageable bounds: California MDL produces $1-3B verdicts; total outflows reach $4-6B/yr for 5 years; FCF redirected from buybacks/M&A; share count stops declining. Combined S&P pressure on AAA credit rating, J&J trades 16-17x EPS (15-20% compression).
• ◆IRA expands to Darzalex in FY2027-2028 negotiation: Darzalex Medicare spend exceeds $1B threshold for negotiation eligibility. $4-6B annual revenue impact directly hits primary growth driver, cutting EPS growth from 7% to 3%.
• ◆Pipeline failures (Milvexian Phase 3 + others): If Factor XIa shows non-inferiority without safety advantage, stroke prevention use case collapses. Icotrokinra fails to penetrate biologic patient population—immunology revenue remains permanently below pre-Stelara levels.

“Primary debate: Is J&J's talc overhang appropriately priced or does it justify permanent discount? Bulls: At $20B FCF, even $25B aggregate talc exposure over 5-7 years is survivable; Risperdal/opioid precedent suggests $10-15B base case; post-resolution stock trades 22-24x forward EPS ($242-280 FY2026E or $280-330 FY2027E). Bears: Three failed bankruptcy attempts and jury verdict variability ($40M vs. $250K in same month) signal resolution further out than hoped; every year of unresolved litigation diverts FCF from buybacks/M&A. Resolution: Talc overhang likely overdiscounted at 19.6x vs. 21-22x historical. Implied discount assumes $15-20B litigation NPV—high end of realistic. Settlement at $10-12B unlocks 22-24x multiple, fair value $250-270 on current estimates.”

• ◆Q2 2026 Earnings (mid-July): Revenue ≥$24.5B + Darzalex +20%+ would confirm base case; guide cut or deceleration triggers review
• ◆TAR-200 Phase 3 readout (H2 2026): Positive bladder cancer data could add $2-3B blockbuster potential; failure removes option value
• ◆Milvexian Phase 3 (2026-2027): Stroke prevention superiority unlocks $5B+ option value; non-inferiority or failure removes largest pipeline asset
• ◆Icotrokinra launch metrics (Q3 2026): Growing prescriptions + biologic conversion signals immunology inflection; weak uptake suggests oral IL-23 not displacing biologics
• ◆DePuy spin-off announcement (H2 2026-2027): Formal structure unveiling could trigger $15-25/share MedTech value unlock
• ◆Talc MDL resolution (2026-2028): Settlement ≤$12B announced removes primary discount factor; multiple expands to 23-24x

• ◆Talc cascade ($25B+ total exposure): 15-20% probability, HIGH severity; kills bull case if annual verdicts exceed $1B in any 3-month period
• ◆IRA Darzalex negotiation (20-25% probability, HIGH): FY2027-2028 selection cuts $3-5B revenue and core growth driver; downgrade to HOLD if selected
• ◆Milvexian Phase 3 failure (40-50% probability, MEDIUM): Option value impairment only; normal failure rate already reflected at low valuation
• ◆MedTech China VBP escalation (20-25% probability, LOW): ~5-10% revenue impact; manageable given non-China growth
• ◆M&A overpayment >$20B (10-15% probability, MEDIUM): Leverage and integration risk post-Intra-Cellular; kills AAA if net debt exceeds $40B